Glioma Epidemiology Forecast 2025-2034

Gliomas account for about 75% of all malignant primary brain tumors in adults, with glioblastomas (GBMs) being the most common and aggressive subtype. Glioma epidemiology forecast indicates that this brain tumor is most commonly diagnosed in older adults aged over 65 years and children under the age of 12. Additionally, research suggests that white people may have a higher likelihood of developing gliomas compared to other ethnic groups.

Glioma Epidemiology Forecast Report Coverage

The “Glioma Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of glioma. It projects the future incidence and prevalence rates of glioma across various populations. The study covers age, gender, and type as major determinants of the glioma-affected population. The report highlights patterns in the prevalence of glioma over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of glioma in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Glioma Understanding: Disease Overview

A glioma is a type of brain tumor that originates from glial cells. Gliomas can be malignant (cancerous) or benign (non-cancerous). Glioblastoma is the most well-known and severe form of glioma and causes significant mortality. Symptoms depend on the size of the tumor and its location in the brain and can include headaches, seizures, and changes in mood or cognitive function. Factors like age, ethnicity, and family history can influence the risk of developing gliomas.

Glioma Epidemiology Perspective

The glioma epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for glioma by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for glioma and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Gliomas are estimated to account for about 75% of all malignant primary brain tumors in adults, with glioblastomas considered the most common and aggressive subtype.
• About 12,000 glioblastoma cases are diagnosed annually in the United States, making up 15% of all new brain tumors and 50% of all malignant brain tumors, as per the Central Brain Tumor Registry of the United States (CBTRUS) Statistical Report published in Neuro-oncology (2021).
• According to the Brain Tumor Society, over 14,490 people in the United States are estimated to receive a glioblastoma diagnosis in 2023.

Age-Based Glioma Insights

Wild-type isocitrate dehydrogenase glioblastoma (IDHwt GBM) is reported as the most prevalent type of primary malignant brain cancer, making up over 90% of glioblastoma cases in adults. The median age of diagnosis is reported to be 68 to 70 years, and older age is linked to a worse prognosis for patients with this glioblastoma type, according to a study published in Neuro-oncology Advances (2021).

Gender-Based Glioma Insights

As per Wang, Gi-Ming et al. (2021), the incidence of glioma is higher in males, with the male-to-female incidence being lowest in children aged 0-9 years and increasing with age, reaching its peak in the 50-59 age group. Females had worse survival in the 0-9 age group, while males had worse survival outcomes in all other age groups.

Country-wise Glioma Epidemiology Segment

The glioma epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of glioma varies between countries, owing to differences in factors such as genetic predispositions, environmental exposures, diet and lifestyle factors, healthcare access, and early detection practices. According to the Cleveland Clinic, approximately 80,000 people in the United States are diagnosed with primary brain tumors annually. Of these, 25% are gliomas, accounting for 20,000 new glioma cases each year.

Key Questions Answered

• What are the key findings of glioma epidemiology in the 8 major markets?
• What will be the total number of patients with glioma across the 8 major markets during the forecast period?
• What was the country-wise prevalence of glioma in the 8 major markets in the historical period?
• Which country will have the highest number of glioma patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of glioma during the forecast period of 2025-2034?
• What are the currently available treatments for glioma?
• What are the disease risks, signs, symptoms, and unmet needs of glioma?

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of glioma based on several factors.
• Glioma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of glioma are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.